Hirotaka Kashima

Dr. Hirotaka Kashima

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2025 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
TYTakaaki Yoshikawa
Takaaki Yoshikawa
TUTakahiro Utsumi
Takahiro Utsumi
TITakahiro Inoue
Takahiro Inoue
NANobukazu Agatsuma
Nobukazu Agatsuma
YTYukari Tanaka
Yukari Tanaka
KPKonoe Project
Konoe Project

1 June 2026 in Clinical Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
HKHirotaka Kashima
Hirotaka Kashima
TUTaro Ueo
Taro Ueo
AFAkihisa Fukuda
Akihisa Fukuda
HSHiroshi Seno
Hiroshi Seno

15 April 2025 in Clinical Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
HKHirotaka Kashima
Hirotaka Kashima
AFAkihisa Fukuda
Akihisa Fukuda
TUTaro Ueo
Taro Ueo
RMRyuki Minami
Ryuki Minami
MOMasaya Ohana
Masaya Ohana
HSHiroshi Seno
Hiroshi Seno

3 May 2026 in Clinical Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
HKHirotaka Kashima
Hirotaka Kashima
AFAkihisa Fukuda
Akihisa Fukuda
TKTakafumi Kurokami
Takafumi Kurokami
MSMakoto Suzuki
Makoto Suzuki
KOKazuya Ohno
Kazuya Ohno
HSHiroshi Seno
Hiroshi Seno

14 August 2025 in Clinical Journal of Gastroenterology
Verified
Journal Article
Closed access
HKHirotaka Kashima
Hirotaka Kashima
AFAkihisa Fukuda
Akihisa Fukuda
RMRyuki Minami
Ryuki Minami
MOMasaya Ohana
Masaya Ohana
TUTaro Ueo
Taro Ueo
HSHiroshi Seno
Hiroshi Seno

7 April 2026 in Cancers
Verified
Journal Article
Open access
PDF file
HKHirotaka Kashima
Hirotaka Kashima
MKMunenori Kawai
Munenori Kawai
KIKei Iimori
Kei Iimori
MNMunemasa Nagao
Munemasa Nagao
TMTakamitsu J Morikawa
Takamitsu J Morikawa
HSHiroshi Seno
Hiroshi Seno
Backgrounds and Aim: Pancreatic cancer is frequently diagnosed at advanced stages, highlighting the need for biomarkers that are capable of detecting early-stage disease in asymptomatic individuals. Recently, apolipoprotein A2 isoforms (ApoA2-ATQ/AT) have been reported as a new blood biomarker for pancreatic cancer. We recently developed diagnostic models based on 100 highly expressed serum microRNAs (miRNAs) combined with CA19-9; these models achieved high accuracy in terms of distinguishing individuals with pancreatic cancer from healthy individuals. This study aimed to compare the diagnostic performance of these miRNA-based models with that of the ApoA2-ATQ/AT biomarker. Methods: Comprehensive sequencing of serum miRNAs was conducted using samples from 120 pancreatic cancer patients recruited across 14 hospitals, along with 93 healthy controls without cancer. Serum CA19-9 levels, miRNA index values, miRNA+CA19-9 index values, and ApoA2 index values were assessed. miRNA-based indices were derived from classification models built on an automated machine-learning platform. Results: The miRNA model (AUC 0.94; 95% CI 0.91–0.97) and the miRNA+CA19-9 model (AUC 0.99; 95% CI 0.98–1.00) outperformed ApoA2 (AUC 0.89; 95% CI 0.84–0.93) in terms of distinguishing individuals with pancreatic cancer from healthy controls across all stages. In early-stage disease (stages 0–I and 0–II), both miRNA-based models also demonstrated superior performance. Strong negative correlations were observed between the ApoA2 index and both the miRNA model index (r = −0.62) and the miRNA+CA19-9 index (r = −0.63). Conclusions: These findings suggest that miRNA-based diagnostic models, particularly when combined with CA19-9, could serve as powerful tools for the early detection of pancreatic cancer.